Title: development of novel anticancer agent to potentiate sensitivity to anti-estrogen therapy
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261201400040C
- Awardee
-
A&G Pharmaceutical, Inc. UEI SN6SWFABJXL1
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,454,426
Award facts
- Opportunity
-
- N44CO4700413 Solicitation number
- Amendment No. 4 Award Notice · Posted Jan 10, 2014
- Contract value 100% obligated
- $1,454,425.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 2 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Columbia, MD 21045, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$24,126 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $1,478,552 |
Quick answers
Who was awarded contract HHSN261201400040C?
HHSN261201400040C was awarded to A&G Pharmaceutical, Inc. by National Cancer Institute (National Institutes of Health) on September 19, 2014.
How much is contract HHSN261201400040C worth?
The government has obligated $1,454,426 on HHSN261201400040C.
Was contract HHSN261201400040C competed?
The extent of competition for HHSN261201400040C was full and open competition after exclusion of sources. The government received 2 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award